Takeda Pharmaceutical Company(TAK)
$21.64+0.05 (+0.23%)
TAK
Takeda Pharmaceutical Company stock drug pipeline
$21.64
At close:+0.05 (+0.23%)
Want to see TAK full AI Analyst Report?
Takeda Pharmaceutical Company (TAK) Drug Pipeline
1,372 Followers
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Takeda Pharmaceutical Company (TAK) have in its pipeline
Takeda Pharmaceutical Company TAK is currently developing the following drugs: Rusfertide, Ptg-300, Zasocitinib, Tak-279, Rusfertide, Tak-360, Elritercept, Tak-226, Mezagitamab, Tak-079, Epoetin Alfa, Elritercept, Tak-505, Tak-279, Zasocitinib, Tak-755, Tak-861, Tak-226, Elritercept, Zasocitinib, Tak-781, Vortioxetine Tablets, Tak-188, Ibi363, Control Arm, Tetravalent Dengue Vaccine, Igi, 10%, Mezagitamab, Tak-411, Active Comparator, Zasocitinib, Vedolizumab Iv, Vedolizumab Sc, Tdv, Fruquintinib, Elritercept, Vedolizumab, Concomitant Antibiotic Therapy, Maribavir, Vedolizumab Sc, No Intervention, Tak-853, Mirvetuximab Soravtansine. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

